All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit Know AML
During the 62nd American Society of Hematology (ASH) Annual Meeting and Exposition, the AML Hub spoke to Uwe Platzbecker, University of Leipzig Medical Center, Leipzig, DE, about the highlights for patients with TP53-mutated AML from ASH 2020.
ASH 2020: Highlights for patients with TP53-mutated AML
Platzbecker highlights the findings from a study evaluating the combination of azacitidine and magrolimab in patients with AML, including TP53-mutant AML.
Treatment of older or unfit patients with AML
Prof. Courtney DiNardo, MD Anderson Cancer Center, Houston, US, discussed the optimal treatment strategy for elderly or frail patients with AML at the 1st NCRI AML academy.
Prof. Uwe Platzbecker | ASH 2016 | 2nd line treatment after ATO + ATRA combination
Dr Uwe Platzbecker talks about possible 2nd line treatment options for patients that might relapse after first line treatment with ATO + ATRA combination.
Subscribe to get the best content related to AML delivered to your inbox